Dupilumab and Lymphoma Risk in AD?

Dupilumab is safe from a lymphoma-risk perspective in atopic dermatitis and other type 2 inflammatory diseases, based on real-world data.

1

Dupilumab treatment does not increase lymphoma risk in patients with atopic dermatitis or other type 2 inflammatory diseases.
2

Atopic dermatitis is associated with a significantly increased risk of lymphoma, including cutaneous T-cell lymphoma and non-Hodgkin lymphoma.
3

The study utilized the TriNetX database and included 801,508 cases and controls to analyze lymphoma risk in type 2 inflammatory diseases.
4

Dupilumab exposure tended to reduce lymphoma risk, particularly in patients with nondermatologic type 2 inflammatory diseases.
5

The findings support the safety of dupilumab, showing no increased lymphoma risk compared to other systemic treatments.

1